Bilieye

Bilieye is redefining neonatal care with a revolutionary, non-invasive app that allows parents and healthcare providers to monitor a baby’s bilirubin levels remotely using just a photo of the baby’s eyes. Bilirubin, a substance in the blood, can indicate liver dysfunction or conditions like jaundice when present in high levels. Jaundice is common in newborns, affecting 60-80% of babies during their first week of life. Currently, bilirubin levels are monitored through invasive blood tests that often require painful heel pricks, repeated hospital visits, and added stress for families. Bilieye cutting-edge technology provides a simple, stress-free alternative, allowing parents to take a quick photo of their baby’s eyes with their smartphone to monitor bilirubin levels accurately and safely. Its software is designed to work for babies of all skin tones, ensuring that every family has access to this essential health monitoring tool. The company's mission is to enhance the healthcare experience for families by providing a safe, effective, and accessible alternative to traditional bilirubin monitoring.

Bilieye has raised $700K in total funding across 1 rounds. The company is currently at the Pre-Seed stage.

Bilieye was founded in 2024 by Chen Binyamin (Co-founder).

Bilieye operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Platforms & Interfaces, Software. Target customers: Consumers, Demographics & Family, Babies, Healthcare & Life Sciences, Healthcare, Patients.

Bilieye is based in Haifa, Israel, North District.